ANDA 78257, held by Onesource Specialty. Ondansetron Hydrochloride.
As of Nov 16, 2026, ANDA 78257 (Ondansetron Hydrochloride), held by Onesource Specialty, was first approved by FDA on Apr 23, 2008, with 5 approved supplements and 0 published complete response letters.
Click here to enter Indications Ondansetron injection is a 5-HT 3 receptor antagonist indicated for the prevention of: nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy. postoperative nausea and/or vomiting. 1.1 Prevention of Nausea and Vomiting Associated With Initial and Repeat Courses of Emetogenic Cancer Chemotherapy Ondansetron injection is indicated for the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including high-dose cisplatin. Ondansetron injection is approved for patients aged 6 months and older. 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 23, 2008 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ondansetron HydrochlorideEQ 2MG BASE/ML · injectable;injection | Ondansetron Hydrochloride | Discontinued |
| Apr 15, 2026 | Supplement 10Labeling · Standard review | Approved | None posted |
| May 1, 2023 | Supplement 6Labeling · Standard review | Approved | None posted |
| May 1, 2023 | Supplement 8Labeling · Standard review | Approved | None posted |
| Oct 26, 2015 | Supplement 4Labeling · Standard review | Approved | None posted |
| Dec 10, 2013 | Supplement 3Labeling · Standard review | Approved | None posted |
| Apr 23, 2008 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters